Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


For Immunization Managers


Facebook
        Twitter
        LinkedIn
        Syndicate





Technical Notes for NIS Surveillance Tables										Related Pages
										On This Page
			Coverage Estimate Methodology and 95% Confidence Interval (CI)Race/ethnicityAgeVaccine Abbreviations
		
Coverage Estimate Methodology and 95% Confidence Interval (CI)
The NIS samples part of the population. It does not collect data for the entire population. The NIS national sample contains approximately 26,000 completed household interviews. National coverage estimates are based on the subsample of approximately 15,000 children with adequate provider data. Vaccination coverage estimates are based on provider-reported vaccination histories. Complex statistical methods are used to adjust for children whose parents did not participate in the survey, lived in households without telephones, or had immunization histories that were not reported by their providers.
Vaccination coverage estimates are presented as a point estimate (%) with a 95% CI. Sample estimates and population values may be different. Part of the difference may be measured through the 95% CI around the estimate. The 95% CI is a measure of precision. Wide confidence intervals are a sign of a relatively small sample size and relatively less precision.
National vaccination coverage estimates are based on a larger sample size, have much smaller (less than ± 1%) confidence intervals, and are more precise than state or local area estimates. For example, in 2015, the vaccination coverage estimate for ≥1 dose of measles, mumps, and rubella vaccine among children 19-35 months in the United States was 91.9% +/-0.8%. This means that the true coverage was probably between 91.1% and 92.7%. The same survey year, the vaccination coverage estimate for ≥1 dose of measles, mumps, and rubella vaccine among children 19-35 months in Connecticut was 97.5% +/-2.4%. This means that the true coverage was probably between 95.1% and 99.9%.
If an estimate is reported as NA (Not Available), the estimate was not reported because it may not be reliable or precise. If the unweighted sample size for the numerator was less than 30 or the (CI half-width)/Estimate was greater than 0.6, the estimate may not be reliable or precise. The estimate for such a subgroup is not reported. The individuals are still included in the overall sample and the overall estimate. State estimates with a CI half-width greater than 10 may be unreliable, but are reported and marked by a footnote.
Race/ethnicity
The child’s race/ethnicity was reported by the parent or guardian responding to the survey. Hispanic children can be of any race. Children identified as multiple races had more than one race category selected. Children identified as white, black, Asian, Native Hawaiian/other Pacific Islander, American Indian/Alaska Native, or multiple races were non-Hispanic.
Age
Starting in the 2011 data collection year, children were age eligible to be included in the survey if they were born from January, three years prior to the start of the survey, through May, one year prior to the start of the survey. For example, children in the survey period from January through December 2015 were born from January 2012 through May 2014.
Prior to the 2011 data collection year, children were age eligible to be included in the survey if they were born from February, three years prior to the start of the survey, through May, one year prior to the start of the survey. For example, children in the survey period from January through December 2010 were born from February 2007 through May 2009.
Top of Page
Vaccine Abbreviations
**DTap: diphtheria and tetanus toxoids and acellular pertussis vaccine (includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine)**
≥1 dose DTaP vaccination: 1 or more doses of DTaP
≥2 doses DTaP vaccination: 2 or more doses of DTaP
≥3 doses DTaP vaccination: 3 or more doses of DTaP
≥4 doses DTaP vaccination: 4 or more doses of DTaP

**Polio: poliovirus vaccine**
≥1 dose Polio vaccination: 1 or more doses of polio
≥2 dose Polio vaccination: 2 or more doses of polio
≥3 dose Polio vaccination: 3 or more doses of polio

**MCV: measles containing vaccine**
**MMR: measles-mumps-rubella vaccine**
≥1 dose MMR vaccination: 1 or more doses of MMR

**Hib:*****Haemophilus influenzae*****type b vaccine**
≥1 dose Hib vaccination: 1 or more doses of Hib
≥2 dose Hib vaccination: 2 or more doses of Hib
≥3 dose Hib vaccination: 3 or more doses of Hib

**Hib-PS vaccination: Primary series of Hib (≥2 or ≥3 doses, depending on product type)**
Hib-FS vaccination: full series of Hib (3 or 4 doses, depending on product type received)

**HepB: hepatitis B vaccine**
Hepatitis B Birth Dose vaccination: HepB administered from birth through age 3 days.
≥1 dose Hepatitis B Vaccination: 1 or more doses of HepB
≥2 dose Hepatitis B Vaccination: 2 or more doses of HepB
≥3 dose Hepatitis B Vaccination: 3 or more doses of HepB

**VAR: varicella vaccine**
≥1 Varicella vaccination: 1 or more doses of varicella vaccine received at or after age 12 months, unadjusted for history of varicella illness
PCV: pneumococcal conjugate vaccine
≥1 dose PCV vaccination: 1 or more doses of PCV
≥2 dose PCV vaccination: 2 or more doses of PCV
≥3 dose PCV vaccination: 3 or more doses of PCV
≥4 dose PCV vaccination: 4 or more doses of PCV

**HepA: hepatitis A vaccine**
≥1 dose Hepatitis A Vaccination: 1 or more doses of HepA
≥2 dose Hepatitis A Vaccination: 2 or more doses of HepA

**Rotavirus vaccination: 2 or more or 3 or more doses of Rotavirus vaccine, depending on the product type received (≥2 doses for Rotarix [RVI] or ≥3 doses for RotaTeq [RV5])**

**Combined 3 vaccine series (4:3:1): 3 or more doses of DTaP, 3 or more doses of Polio, and 1 or more doses of MMR**
Combined 4 vaccine series (4:3:1:3*): 4 or more doses of DTaP, 3 or more doses of Polio, 1 or more doses of MMR, and Hib full series (3 or 4 doses, depending on product type received) (In 2013 data, referred to as 4:3:1:4-FS)
Combined 5 vaccine series (4:3:1:3*:3): 4 or more doses of DTaP, 3 or more doses of Polio, 1 or more doses of MMR, Hib full series (3 or 4 doses, depending on product type received), and 3 or more doses of HepB (In 2013 data, referred to as 4:3:1:4:3-FS)
Combined 6 vaccine series (4:3:1:3*:3:1): 4 or more doses of DTaP, 3 or more doses of Polio, 1 or more doses of MMR, Hib full series (3 or 4 doses, depending on product type received), 3 or more doses of HepB, and 1 or more doses of Varicella (In 2013 data, referred to as 4:3:1:4:3:1-FS)
Combined 7 vaccine series (4:3:1:3*:3:1): 4 or more doses of DTaP, 3 or more doses of Polio, 1 or more doses of MMR, Hib full series (3 or 4 doses, depending on product type received), 3 or more doses of HepB, 1 or more doses of Varicella, and 4 or more doses of PCV (In 2013 data, referred to as 4:3:1:4:3:1:4-FS)
							
					
						Page last reviewed:  October 6, 2016					Content source: 	National Center for Immunization and Respiratory Diseases homeImmunization Managers Home
Price Lists & Vaccine Codes
Vaccination Coverageplus icon
ChildVaxView
SchoolVaxView
TeenVaxView
AdultVaxView
FluVaxView
COVIDVaxView
RSVVaxView
Program Contacts
Requirements & Lawsplus icon
State Vaccination Requirementsplus icon
Selected References
HIPAA Overviewplus icon
Access to Patient Records during IQIP & VFC Visits
Perinatal Hepatitis B Prevention
Program Components
Awardee Immunization Websites
Guidelines and Publications Vaccines & ImmunizationsVaccine SafetyImmunization Action CoalitionExternalAIMExternalVaccine Education CenterExternal


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue